miR-143 and miR-145 | AS oligonucleotide, experimental therapy | Koo et al. (2012) BMC Cancer 12:143 |
miR-1275 | AS oligonucleotide, experimental therapy | Katsushima et al. (2012) J Biol Chem 2012 Jun 26 [Epub] |
PTBP1 | AS oligonucleotide, experimental therapy | Izaquirre et al. (2012) Mol Carcinog 51(11):895 |
miR-21 | AS oligonucleotide, experimental therapy | Zhou et al. (2012) Zhonqhua Znonq Liu Za Zhi 33(10):74 |
ATM | AS vector, experimental therapy | Chuah et al. (2012) Int J Oncol 40(6):1963 |
miR-143 &-145 | AS vector, experimental therapy | Koo et al. (2012) BMC Cancer 12:143 |
18-kDa-TSPO | AS vector, experimental therapy | Veenman et al. (2012) Pharmacogenet Genomics 22(8):606 |
miR-1275 | AS oligonucleotide, experimental therapy | Katsushima et al. (2012) J Biol Chem 287(33):27396 |
miR-21 | AS oligonucleotide, experimental therapy | Wong et al. (2012) Anticancer Res 32(7):2835 |
Metallo-thionein 1E | AS vector, experimental therapy | Ryu et al. (2012) Int J Oncol 41(4):1305 |
miR-92a | AS oligonucleotide, experimental therapy | Niu et al. (2012) Oncol Rep 28(5):1771 |
14-3-3-beta | AS vector, experimental therapy | Park et al. (2012) Neurol Res 34(9):893 |
MMP-9 | AS vector, experimental therapy | Sun et al. (2013) 29(1):83 |
miR106b | AS oligonucleotide, experimental therapy | Zhang et al. (2013) J Neuro-oncol 112(2):179 |
miR-30a-5p | AS oligonucleotide, experimental therapy | Jia et al. (2013) PLoS One 8(1):e55008 |
IGF-I | AS vector, experimental therapy | Pan et al. (2013) PLoS One 8(3):e58428 |
EGF-R | AS vector, experimental therapy | Kalman et al. (2013) Neuromolecular Med 15(2):420 |
miR-21 | AS oligonucleotide, experimental therapy | Costa et al. (2013) Mol Ther Nucleic Acids 2:e100. |